#

Over 20 years of experience.

More than 30 clinical trials

FDA, EMA & ANMAT regulatory compliance

92 %

Completed projects

71 %

Exceeded the objectives

Sponsors & CROS

View More

Management and professionalism, which allow to increase the speed and consistency of the results:

  • SPONSOR: GSK
  • STUDY: B WELL 1 / 202009
  • CONDITION: Chronic hepatitis B treated with nucleoside/nucleotide analogs
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • OVERCOME: 3
  • SPONSOR: Eli Lilly
  • STUDY: J3L-MC-EZEF / ACCLAIM-Lp(a)
  • CONDITION: Atherosclerotic cardiovascular disease
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET: 4
  • OVERCOME: 5
  • SPONSOR: Eli Lilly
  • STUDY: ACHIEVE-4 / J2A-MC-GZGS
  • CONDITION: Type 2 diabetes and obesity or overweight, with increased cardiovascular risk
  • DRUG: LY3502970 administered once daily compared to insulin glargine
  • STATUS: Enrollment closed
  • ENROLLMENT TARGET: Expected inclusion
  • OVERCOME: 11
  • SPONSOR: ROCHE
  • STUDY: LUCERNE
  • CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • DRUG: FARICIMAB
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 5 PATIENTS
  • FULFILLED: 5 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: AVONELLE
  • CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • DRUG: FARICIMAB (LUCERNE extension)
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 4 PATIENTS
  • FULFILLED: ✅ 4 PATIENTS
  • SPONSOR: ALVOTECH
  • STUDY: AV706-GL-C01
  • CONDITION: WET NEOVASCULAR MACULAR DEGENERATION
  • DRUG: AVT06 compared to EU-EYLEA
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 3 PATIENTS
  • EXCEEDED: ✅ 5 PATIENTS
  • SPONSOR: OPTHEA
  • STUDY: COAST
  • CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • DRUG: OPT-302
  • STATUS: ONGOING / RECRUITMENT OPEN
  • ENROLLMENT TARGET: 5 PATIENTS
  • FULFILLED: ✅ 4 PATIENTS
  • SPONSOR: IVERIC BIO
  • STUDY: ISEE_2008
  • CONDITION: GEOGRAPHIC ATROPHY
  • DRUG: ZIMURA
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 3 PATIENTS
  • FULFILLED: ✅ 3 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: SANDCAT
  • CONDITION: UVEITIC MACULAR EDEMA
  • DRUG: RO07200220
  • STATUS: ONGOING / RECRUITMENT OPEN
  • TARGET: 5 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: ALLUVIUM
  • CONDITION: DIABETIC MACULAR EDEMA
  • DRUG: RO7200220
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 5 PATIENTS
  • EXCEEDED: ✅ 10 PATIENTS
  • SPONSOR: OCUDYNE, INC
  • STUDY: OC-1901AR
  • CONDITION: AGE-RELATED MACULAR DEGENERATION
  • DRUG: SURGICAL INTERVENTION PROCEDURES
  • STATUS: ONGOING / RECRUITMENT OPEN
  • EXCEEDED: ✅ 4 PATIENTS
  • SPONSOR: Roche
  • STUDY: SATRAGO / GP44467
  • CONDITION: Thyroid Eye Disease
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • INCLUDED: 2
  • SPONSOR: Novo Nordisk
  • STUDY: REIMAGINE 4
  • CONDITION: Efficacy and Safety of cagrilintide and semaglutide 2.4 mg
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • OVERCOME: 15
  • SPONSOR: OTX
  • STUDY: OTX-TKI-2023-AMD-301
  • CONDITION: Age-related neovascular macular degeneration
  • DRUG:
  • STATUS: Enrolling
  • ENROLLMENT TARGET:
  • INCLUDED:
  • SPONSOR: SANTEN
  • STUDY: LUMINA
  • CONDITION: ACTIVE INFECTIOUS POSTERIOR SEGMENT UVEITIS
  • DRUG: 440 ug of DE-109
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 3 PATIENTS
  • EXCEEDED: ✅ 6 PATIENTS
  • SPONSOR: NOVARTIS
  • STUDY: KESTREL
  • CONDITION: DIABETIC MACULAR EDEMA
  • DRUG: BROLUCIZUMAB versus AFLIBERCEPT
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 10 PATIENTS
  • EXCEEDED: ✅ 24 PATIENTS
  • SPONSOR: APELLIS
  • STUDY: APL-303
  • CONDITION: GEOGRAPHIC ATROPHY SECONDARY TO AMD
  • DRUG: PEGCETACOPLAN
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 6 PATIENTS
  • EXCEEDED: ✅ 11 PATIENTS
  • SPONSOR: APELLIS
  • STUDY: APL2-305-GALE
  • CONDITION: GEOGRAPHIC ATROPHY SECONDARY TO AMD
  • DRUG: PEGCETACOPLAN (APL-303 Extension)
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 6 PATIENTS
  • EXCEEDED: ✅ 9 PATIENTS
  • SPONSOR: ALVOTECH
  • STUDY: AV706-GL-C01
  • CONDITION: WET NEOVASCULAR MACULAR DEGENERATION
  • DRUG: AVT06 compared to EU-EYLEA
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 3 PATIENTS
  • EXCEEDED: ✅ 5 PATIENTS
  • SPONSOR: NOVARTIS
  • STUDY: CONDOR
  • CONDITION: BROLUCIZUMAB 6mg compared to LASER Photocoagulation
  • DRUG: BROLUCIZUMAB 6mg
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 10 PATIENTS
  • EXCEEDED: ✅ 11 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: BALATON
  • CONDITION: MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
  • DRUG: FARICIMAB
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 4 PATIENTS
  • EXCEEDED: ✅ 8 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: COMINO
  • CONDITION: MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
  • DRUG: FARICIMAB
  • STATUS: COMPLETED
  • ENROLLMENT TARGET: 4 PATIENTS
  • EXCEEDED: ✅ 13 PATIENTS
  • SPONSOR: ROCHE
  • STUDY: BARDENAS
  • CONDITION: DIABETIC MACULAR EDEMA
  • DRUG: RO7200220 in combination with RANIBIZUMAB
  • STATUS: ONGOING
  • ENROLLMENT TARGET: 5 PATIENTS
  • EXCEEDED: ✅ 6 PATIENTS

Contact

These are our contact channels.
We will be in touch very soon with you!

981 Arenales, 4th Floor, Buenos Aires, Argentina

info@bamsite.com.ar

54 9 11 5565 6846